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Keypoints 48 
• Two thirds of PCNSL have BCRs specific for SAMD14 and neurabin-I, two 49 
highly homologous CNS proteins.  50 
• Both antigens were posttranslationally modified and induced a strong BCR 51 
pathway activation and proliferation. 52 
 53 
Abstract 54 
To address the role of chronic antigenic stimulation in PCNSL we searched for auto-55 
antigens and identified SAMD-14 and neurabin-I as auto-antigenic targets of the B-56 
cell receptors (BCRs) from 8/12 PCNSLs. In the respective cases SAMD14 and 57 
neurabin-I were atypically hyper-N-glycosylated (SAMD14 at ASN339 and neurabin-I 58 
at ASN1277) explaining their auto-immunogenicity. SAMD14 and neurabin-I induced 59 
BCR pathway activation and proliferation of aggressive lymphoma cell lines 60 
transfected with SAMD14 and neurabin-I reactive BCRs. Moreover, the BCR binding 61 
epitope of neurabin-I conjugated to a truncated pseudomonas exotoxin killed 62 
lymphoma cells expressing the respective BCRs. These results support the role of 63 
chronic antigenic stimulation by posttranslationally modified CNS driver auto-antigens 64 
in the pathogenesis of PCNSL, serve as an explanation for their CNS tropism and 65 
provide the basis for a novel specific treatment approach. 66 
 67 
Introduction 68 
PCNSL is a rare aggressive B-cell non-Hodgkin lymphoma affecting the brain, the 69 
leptomeninges, the spinal cord or the eyes. Recently high frequency of activating 70 
CD79b and MYD88 mutations linking the BCR and TLR9 pathways and high 71 
expression of PDL1 were reported.1;2 The reason for the selective tropism in the 72 
CNS, which is traditionally regarded as an immune privileged site, is still unclear. The 73 
tetrad of overrepresentation of autoreactivity-linked VH4-34, persistent functional 74 
variable region genes despite ongoing somatic hypermutation, the negativity for EBV, 75 
and the transcriptional upregulation of the NF-kB pathway suggest chronic B-cell 76 
receptor activation and prompted us to search for antigens of the BCRs from 77 
PCNSL.3-6 The hypothesis of chronic BCR stimulation contributing to the malignant 78 
transformation of B cells is old 7 and several specific target antigens of BCR from 79 
various B-NHLs have been identified.8-11 A recently published study proposed auto- 80 




The study had been approved by the local ethics committee (Ärztekammer des 85 
Saarlandes). Snap-frozen PCNSL specimens from 21 HIV-negative patients were 86 
obtained from the institutes of pathology and neuropathology of the universities of 87 
Saarland, Kiel, Würzburg and Erlangen. Pairs of serum and CSF samples from a 88 
second series of 22 PCNSL patients were obtained from the Department of 89 
neurology of Tübingen University. Additional sera and whole blood samples were 90 
obtained from the Departments of Hematology & Oncology of Freiburg and Saarland 91 
Universities. Sera from patients with secondary CNS manifestations or with testicular 92 
manifestations of DLBCL treated within the RICOVER-60 13 trial of the DSHNHL 93 
served as a control. Blood Samples of multiple sclerosis were obtained from the 94 
department of neurology of Saarland Medical school. Cryospecimen of primary 95 
testicular lymphoma were obtained from the institutes of pathology of the universities 96 
of Würzburg and Ulm. Recombinant Fabs of other B cell neoplasia as controls for 97 
PCNSL were constructed in cooperation with the Secnkenberg institut of pathology of 98 
the Goethe university in Frankfurt a.M. 99 
 100 
Ig variable region gene PCR 101 
Fragments of PCNSL cryosections were digested with 2 µl of proteinase K (Roche 102 
PCR grade) for 4h at 55°C followed by heat-inactivation at 95°C for 10min. Semi-103 
nested PCRs for VH, Vκ and Vλ genes were performed (30 and 44 cycles, 104 
respectively) using Expand High Fidelity PCR kit (Roche) as described by Küppers et 105 
al.
14;15 The resulting variable region genes were sequenced and analyzed with IMGT-106 
V-Quest for functionality, V(D)J segment usage, and mutations. Whenever both a 107 
functional Ig heavy and light chain variable region gene were obtained, these genes 108 
were cloned into a modified pCES vector for the expression of recombinant BCRs as 109 
Fab fragments.16 Fabs were expressed and purified as described previously.17 110 
Variable gene fragments were re-extended at the 5′ and 3′ ends according to the 111 
proper immunoglobulin germline genes. Complete V genes were inserted via ApaLI 112 
and XhoI for Vκ or Vλ in front of a κ- or λ-constant region gene, respectively and via 113 
NcoI and BstEII for VH in front of a γ-1 constant region gene into a modified pCES-1 114 
vector for expression of the Fab fragment.16 Fabs were expressed in E. coli TG1 115 
strain and purified as described previously. 16;18;19 116 
 117 
Screening for antigenic BCR targets 118 
Pooled recombinant PCNSL-BCRs (each at a concentration of 10 µg/ml) were 119 
screened on protein macroarrays representing clones of UniPEx human cDNA 120 
expression libraries expressed in E. coli (Bioscience, Dublin, Ireland) as described 121 
before. 10;11;20  122 
 123 
ELISA for BCR and serum antibody reactivity against SAMD14 and neurabin-I  124 
SAMD14 and neurabin-I were recombinantly expressed with a C-terminal FLAG tag 125 
in HEK293 under the control of a CMV promoter (pSFI). Total cell extracts were 126 
bound at a concentration of 10 µg/ml to Nunc Maxisorb plates pre-coated overnight 127 
at 4°C with murine anti-FLAG antibody at a dilution of 1:2,500 (v/v; Sigma, Munich). 128 
Blocking was performed with 1.5% (w/v) gelatin in TBS and washing steps were 129 
performed with TBS-Tx [TBS, 0.1% (v/v) Tx100]. Individual recombinant Fabs (10 130 
µg/ml), sera (1:100) and CSF (1:50) were used. ELISAs were conducted according to 131 
standard protocols with biotinylated goat anti-human IgG (heavy and light chain), 132 
goat anti-human IgA and anti-human IgM (all Dianova), all at dilutions of 1:2,500, or 133 
subclass-specific sheep anti-human IgG1, IgG2, IgG3 and IgG4 (Binding Site, 134 
Birmingham, UK) at dilutions of 1:5,000. Following this, correspondent biotinylated 135 
secondary antibodies were used for the immunoassays for IgG subclasses. For 136 
detection, peroxidase-labeled streptavidin (Roche) was used at a dilution of 1:50,000.  137 
 138 
Identification of the BCR-binding epitope of SAMD14 and neurabin-I 139 
For the determination of the binding region of SAMD14 and neurabin-I, recombinant 140 
fragments of different lengths from both antigens were constructed with C-terminal 141 
FLAG tags and expressed as described above.  142 
 143 
Western blots of SAMD14 and neurabin-I 144 
Lysates of PCNSL tissue specimens, whole peripheral blood cells or LCLs were 145 
loaded and separated in a 10% SDS-PAGE and transferred to PVDF membrane 146 
using a transblot semi-dry transfer cell (Bio Rad). After blocking overnight at 4°C in 147 
PBS/10% non-fat dry milk, transferred proteins were incubated with recombinant 148 
SAMD14/neurabin-I reactive BCRs at a concentration of 2 µg/ml for 1h at room 149 
temperature or with rabbit anti N-terminus neurabin-I antibody (ABIN 1108406) at 150 
1:500 for 1h or with murine anti-FLAG-antibody at 1:2,000 for 1h, followed by 1h 151 
incubation at room temperature with murine anti-His antibody at 1:2,000 (Quiagen), 152 
with HRP-labelled anti mouse IgG antibody (Biorad) for His6-tagged PCNSL-derived 153 
recombinant BCRs, with goat HRP-labelled anti-rabbit antibody (Bio Rad) at 1:3,000 154 
for the anti-neurabin-I antibody, and by HRP-labelled anti-mouse-IgG antibody at 155 
1:3,000 for Western blots with point-mutated FLAG-tagged full-length fragments of 156 
SAMD14 and neurabin-I and the chemiluminescence reagent (NEB) was used for 157 
immunoblot detection.  158 
Moreover, SAMD14 and neurabin-I from >80 established cell lines were screened by 159 
Western blot for N-hyperglycosylation. 160 
 161 
Deglycosylation of SAMD14 and neurabin-I 162 
Equal amounts of denatured lysates from PCNSL specimens were treated with 163 
specific exo- or endoglycosidases, i.e. PNGase-F, o-Glycosidase, α-2(3,6,8,9)-164 
neuraminidase, position-specific β-1-4-galactosidase or β-N-acetylglucosaminidase 165 
(EDEGLY-Kit, Sigma).  166 
 167 
Site-directed mutagenesis 168 
Using QuickChange II Site-Directed Mutagenesis Kit (Stratagene) and SAMD14 and 169 
neurabin-I full-length FLAG-tagged DNA fragments, several candidate N-170 
glycosylation sites within or adjacent to the BCR binding epitopes were mutagenized 171 
after prediction of the most likely glycosylation sites 172 
(http://www.cbs.dtu.dk/services/NetNGlyc/). In each case the amino acid asparagine 173 
(N) was replaced by glutamine (Q), disabling N-glycosylation. This exchange was 174 
performed for SAMD14 with N339Q and N372Q and for neurabin-I with N1208Q, 175 
N1258Q, N1277Q, N1289Q and N1301Q. These FLAG-tagged mutants were cloned 176 
into pRTS and expressed in LCLs derived of patients with N-hyperglycosylated 177 
SAMD14 and neurabin-I (#20) and patient with wt SAMD14 and neurabin-I (#21).  178 
 179 
Lymphoblastoid cell lines 180 
Lymphoblastoid cell lines (LCLs) were established by infection of PBMCs with EBV 181 
as described before.21 182 
 183 
Expression of SAMD14/neurabin-I, MAZ antigens and respective immunotoxins 184 
BCR-binding epitopes of neurabin-I, SAMD14 and MAZ as a control were 185 
recombinantly expressed with C-terminal FLAG tags in HEK293 cells.11 186 
Immunotoxins consisting of the BCR-binding epitope of neurabin-I (amino acids 187 
1226-1251) conjugated to pseudomonas exotoxin A were recombinantly expressed 188 
in E. coli BL21 as described before by others.22  189 
 190 
Expression of SAMD14/neurabin-I reactive BCR in OCI-Ly3, TMD-8 and U2932  191 
As no EBV-negative PCNSL cell line exists to the best of our knowledge, the DLBCL 192 
ABC type cell lines OCI-Ly3, TMD-8 and U2932 were chosen as model cell lines. 193 
OCI-Ly3 harbors mutated MYD88 and CARD11, TMD-8 mutated MYD88, mutated 194 
CD79B, but wild-type CARD11, U2932 mutated TAK1, but wild-type CARD11 and 195 
MYD88.23-26 Each cell line was transfected with a modified pRTS-1 expression vector 196 
with a variable region heavy chain and constant regions Cγ1-Cγ4 with membrane 197 
coding exons TM1 and TM2 for the transmembrane region and the cytoplasmic tail 198 
followed by a 2A sequence and the light chain variable region and light chain 199 
constant region gene inserted via SfiI sites.27 Both VH and Vk were derived from the 200 
SAMD14/neurabin-I reactive PCNSL-BCR from patient #18 or as a control from a 201 
patient with CLL and a BCR directed against MAZ11. Transfection of OCI-Ly3, TMD8 202 
and U2932 cells was performed on ice after 3 washing steps with RPMI at a cell 203 
density of 2 x 10E7/ml in RPMI without FCS. 2 x 10E6 cells were transfected with 5 204 
µg plasmid DNA by electroporation using Gen Pulser (Biorad) with a 0.2 cm cuvette 205 
at 140V with 30 msec pulses. Subsequently, cells were immediately put on ice again 206 
and cultured in RPMI-1640 medium supplemented with 20% FCS. Cell lines stably 207 
expressing surface BCR with reactivity against SAMD14/neurabin-I were selected 208 
with hygromycin 250 µg/ml.28 Successful transfection was verified by variable region 209 
gene PCRs, by Western blot and flow cytometry of the FLAG-tagged recombinant 210 
BCRs. 211 
 212 
Proliferation and BCR pathway activation assays 213 
For Western blot analysis of the BCR pathway activation of transfected OCI-Ly3, 214 
cells either expressing a BCR with reactivity against SAMD14/neurabin-I or a 215 
different antigen, respectively, 1x10E6 cells were incubated with no antigen, 216 
neurabin-I/SAMD14 at 5 µg/ml, MAZ at 5 µg/ml or anti-IgM at 1 µg/ml. For Western 217 
blot analysis of the BCR pathway activation of transfected TMD8 and U2932 cells 218 
either expressing recombinant BCR with reactivity against SAMD14/neurabin-I by 219 
Doxycyclin induction or not expressing recombinant BCR by lack of Doxycyclin 220 
induction, 1x10E6 cells were incubated with no antigen, neurabin-I/SAMD14 at 5 221 
µg/ml, LRPAP1 at 5 µg/ml or anti-IgM at 1 µg/ml. As primary antibodies rabbit 222 
antibodies against pTyr525/526 SYK diluted 1:2000, pTyr759 PLCγ2 diluted 1:1000, 223 
pTyr223 BTK diluted 1:1000 and pTyr96 BLNK diluted 1:1000 (B cell signaling 224 
sampler kit, CST, Massachusetts, USA), rabbit antibody against actin diluted 1:2000 225 
(Sigma) and murine antibody against c-Myc at a concentration of 1µg/ml (Santa 226 
Cruz) were used, followed by washing steps and incubation with POX-conjugated 227 
anti rabbit or anti mouse antibodies diluted at 1:3000. 228 
For the analysis of cytoplasmatic calcium changes by flow cytometry a FACS Canto 229 
analyzer was used and Fluo-4/AM dye. Transfected OCI-Ly3 cells either expressing 230 
BCRs with reactivity against SAMD14/neurabin-I or against MAZ 11 were 231 
resuspended in calcium- and magnesium-free PBS, and loaded with Fluo-4/AM dye 232 
(final concentration 2 µM, Invitrogen) for 30 min at room temperature as described 233 
before.11 Antigen was added followed by flow cytometry of the cells. Ionomycin (10 234 
ng/µl, Sigma-Aldrich) was used as a positive control for the release of calcium from 235 
internal stores. Cytoplasmatic calcium levels were repeatedly analyzed immediately 236 
after adding the antigen to the dye-loaded cells and mixing.  237 
Cell proliferation was determined by a non-radioactive assay (EZ4U, Biomedica) 238 
according to the manufacturer’s instructions In short, 4x104/ml OCI-Ly3 cells 239 
expressing BCRs with reactivity against SAMD14/neurabin-I or MAZ were seeded in 240 
200µl cell cultures. To detect possible quantitative differences between the 241 
recombinantly expressed epitope regions of neurabin-I or MAZ, both were used at a 242 
concentration of 1 µg/ml. After 24 h incubation at 37ºC, 20 µl of chromophore 243 
substrate were added to each well.  244 
 245 
Cytotoxicity, apoptosis and dye exclusion assays  246 
For the analysis of the direct cytotoxic effects of immunotoxins an LDH release assay 247 
was used. 5x10E3/well OCI-LY3, TMD8 or U2932 cells stably transfected with 248 
Doxycycline-inducible expression of a SAMD14/neurabin-I-reactive BCR were 249 
incubated with neurabin-I-ETA’ (5 µg/ml), MAZ-ETA’ (5 µg/ml) or no immunotoxin. 250 
Percent specific lysis was determined as (experimental lysis minus spontaneous 251 
lysis)/(maximum lysis minus spontaneous lysis) × 100. Maximum lysis was 252 
determined by adding 10% Triton X-100. Lactate dehydrogenase (LDH) was 253 
measured according to the protocol of the LDH assay kit (Roche, Mannheim, 254 
Germany). ELISA read out was done using a Victor II (PerkinElmer, Rodgau, 255 
Germany).  256 
For the analysis of apoptosis, 5x10E5 cells/ml suspension of OCI-LY3 cells stably 257 
transfected to express either a BCR with reactivity against the SAMD14/neurabin-I or 258 
against MAZ 11 were treated with neurabin-I/ETA’, MAZ/ETA’ (both at 0.5 µg/ml) or 259 
staurosporin (1 µg/ml) for 24h at 37°C, 5% CO2. Following the incubation, the cells 260 
were washed twice with PBS and resuspended in 500 µl binding buffer. 5 µl of 261 
AnnexinV-FITC and 10µl of propidium iodide were added to each cell suspension 262 
and incubated for 10 min at room temperature, followed by analysis by FACS Canto. 263 
In addition, the effects of the immunotoxins were measured by trypan blue assays at 264 
0, 24 and 48 hours.  265 
 266 
Results 267 
SAMD14 and neurabin-I as antigenic targets of BCRs from PCNSL 268 
The median age of the 21 patients from whom PCNSL specimens were obtained was 269 
64 (range: 36 to 77) years. Functional Ig heavy and light chain genes were 270 
successfully amplified from 12 PCNSL patients, including one case with two 271 
functional heavy chain genes (case 3), and two cases with two functional light chain 272 
genes (case 15 and 17). Four of the 12 (33%) patients had VH gene segments of 273 
VH4-34. All cases with amplified V region genes were somatically mutated: one case 274 
carried an unmutated VH gene, but a mutated Vk segment; two other cases carried 275 
unmutated Vk genes, but mutated VH genes (supplementary table 1). 276 
The screening of the protein macroarrays representing 7,390 distinct human proteins 277 
for reactivity with 12 pooled recombinant PCNSL-derived BCRs identified one 278 
candidate autoantigen with a strong reactivity on the Unipex1 membrane: an 279 
expression clone of SAMD14 variant 2 spanning from amino acids 192 to 417 280 
(Supplementary Figure 1). No reactivities were detected on the Unipex2 membrane. 281 
An ELISA with recombinant SAMD14 variant 2 expressed with a C-terminal FLAG-282 
tag in HEK293 confirmed SAMD14 as the only target antigen of 8/12 (67%) PCNSL-283 
BCRs (Figure 1A).  284 
None of the recombinant control BCRs derived from 12 peripheral DLBCL, 19 MCL, 285 
31 FL and 15 NLPHL cases reacted against SAMD14 (Supplementary Figures 2 and 286 
3). Western blot of denatured PCNSL lysates with the recombinant BCRs as primary 287 
antibodies confirmed reactivity against SAMD14, a protein of 45 kDa. An additional 288 
band of approximately 140 kDa was observed (Figures 1B - D). To investigate if this 289 
was a hypothetical polymer of SAMD14 or the highly homologous SAM domain of 290 
neurabin-I, the Western blot was stripped and repeated with an anti-neurabin-I 291 
antibody reactive against the non-homologous N-terminus of neurabin-I and not the 292 
homologous SAM domain. This identified neurabin-I as a second target containing a 293 
highly homologous SAM domain (Figure 1C). ELISAs with fragments of different 294 
lengths of SAMD14 variant 2 and of neurabin-I identified an epitope spanning from 295 
amino acid 274 to 417 of SAMD14 variant 2 and an epitope spanning from amino 296 
acid 995 to 1345 of neurabin-I (supplementary figures 4 and 5) as the BCR-binding 297 
region. In further analysis for SAMD14 amino acids 306 to 324 and for neurabin-I 298 
amino acids 1226 to 1251 were identified as the regions with the highest affinity. No 299 
reactivities of the PCNSL-BCRs were detected on an infectious disease epitope 300 
microarray. 301 
 302 
Hyper-N-glycoslyation of SAMD14 and neurabin-I  303 
Both SAMD14 variant 2 and neurabin-I had a higher molecular weight in PCNSL 304 
patients with reactive lymphoma BCRs compared to patients without reactive 305 
lymphoma BCRs and healthy controls (Figures 1C and 1E). Deglycosylation with 306 
PNGase F / ß-n-acetylglucosaminidase led to the disappearance of differences in 307 
molecular weights of both SAMD14 and neurabin-I between patients with and without 308 
SAMD14/neurabin-I-reactive lymphomas. Neither deglycosylation with O-309 
glycosidase, α-2(3,6,8,9)-neuraminidase nor β-1-4-galactosidase (Figure 2A and 2B) 310 
induced this disappearance of differences in molecular weights. In 7/15 PCNSL 311 
patients with sufficient material for Western blot analysis, hyperglycosylated SAMD14 312 
and neurabin-I were detected in cryosections and also (yet only weakly) in the 313 
peripheral blood from those patients of whom the latter was available. The 314 
hyperglycosylated SAMD14 and neurabin-I isoforms were also weakly expressed in 315 
monocytes, lymphocytes and granulocytes from PCNSL patients with 316 
SAMD14/neurabin-I-reactive BCRs (supplementary figure 6). Hyperglycosylated 317 
SAMD14/neurabin-I was not observed in the peripheral blood cell lysates from 400 318 
healthy controls, 50 residents of nursery homes, 20 patients with multiple sclerosis, 319 
nor in cryospecimen of four cases of testicular lymphoma, nor in any of >80 320 
established cell lines derived from human malignancies (data not shown). 321 
Subsequently, using patient-derived LCLs and point-mutated FLAG-tagged 322 
constructs of SAMD14 and neurabin-I, Asn 339 was identified to bear the 323 
hyperglycosylated Asn residue of SAMD14, and Asn 1277 of neurabin-I (Figure 2C). 324 
These glycosylation sites consisted of atypical N-L-E-Q.  325 
 326 
Antibody reactivity against SAMD14 and neurabin-I 327 
SAMD14/neurabin-I autoantibodies were frequently detected by ELISA in the sera 328 
and CSF from patients with PCNSL. The sera and CSF from 8/22 (36.4%) patients 329 
from a cohort different from the one from whom the PCNSL specimens were obtained 330 
contained anti-SAMD14/neurabin-I antibodies (supplementary figure 7) as was the 331 
case with 10 sera from a third series of 39 patients with PCNSL, resulting in a total of 332 
18/61 (29.5%) serum antibody-positive patients. Antibody serum titers ranged from 333 
1:800 up to 1:3200 and CSF titers ranged from 1:800 up to 1:1600 (Table 1). The 334 
eight SAMD14/neurabin-I antibody-positive serum/CSF pairs were tested for their Ig 335 
classes and IgG subclasses. All of them were IgG, with 7/8 (87.5%) belonging to the 336 
IgG1 subclass (supplementary figure 8 and 9). There were no SAMD14/neurabin-I 337 
antibodies in the sera from 18 patients with secondary CNS manifestations of 338 
peripheral DLBCL, sera of 24 patients with DLBCL with testicular manifestation, 92 339 
healthy controls and in the sera and CSF of 21 patients with multiple sclerosis 340 
(supplementary figures 10, 11, 12, 13 and 15).  341 
 342 
BCR pathway activation and induction of proliferation by SAMD14 and 343 
neurabin-I  344 
Western blot analysis of the BCR signaling pathway showed a strong activation 345 
following the addition of the cognate antigen neurabin-I to transfected TMD8, U2932 346 
and OCI-Ly3 cells expressing a SAMD14/neurabin-I-reactive BCR as demonstrated 347 
by a strong upregulation of pTyr525/526 SYK, pTyr96 BLNK, pTyr759 PLCγ2 and 348 
pTyr223 BTK and a significant increase in MYC expression (Figure 3A and 349 
supplementary Figure 18). Furthermore, flow cytometric analysis of cytoplasmic 350 
calcium levels of the OCI-Ly3 cells transfected to express a SAMD14/neurabin-I-351 
reactive BCR indicated a strong increase of cytoplasmatic calcium levels after 352 
incubation with SAMD14/neurabin-I, but not the control antigen MAZ (supplementary 353 
Figure 18), which had been shown to be the antigenic target derived from the 354 
malignant cells of a patient with CLL 11. In correspondence to this, incubation with the 355 
BCR-binding neurabin-I epitope resulted in an increased proliferation of the 356 
transfected U2932, TMD8 and OCI-LY3 cell lines expressing SAMD14/neurabin-I-357 
reactive BCR (Figure 3b and supplementary Figure 18) in a tetrazolium formazan 358 
(EZ4U) assay.  359 
 360 
BCR-mediated targeting of PCNSL by BCR antigen / drug conjugates 361 
The transfected cell lines Ocy-Ly3, U2932 and TMD8 expressing a patient-derived 362 
BCR with specificity for SAMD14/neurabin-I were specifically killed by incubation with 363 
a neurabin-I-ETA’ drug conjugate, while remaining unaffected when incubated with 364 
the same toxin conjugated to a irrelevant control antigens (MAZ or LRPAP1). The 365 
specific killing was demonstrated in an LDH release assay (figure 4A). As shown by 366 
trypan exclusion, 100% of the lymphoma cells expressing a BCR with specificity for 367 
SAMD14/neurabin-I were dead after 72 hours of incubation with the BAR-toxin 368 
conjugate (figure 4b). The toxic effect of the neurabin-I/ETA’ was dose-dependant 369 
(Figure 4c). In accordance to this, an increase of apoptotic cells was detected after 370 
incubation with neurabin-I/ETA’ in U2932, TMD8 and OCI-Ly3 cells expressing 371 
SAMD14/neurabin-I-reactive BCRs (Figure 4 d and e and supplementary Figure 19), 372 
as shown by an Annexin-V/PI assay. 373 
 374 
Discussion 375 
We identified the sterile α-motif domain containing protein 14 (SAMD14) and the 376 
highly homologous SAM domain of neural tissue-specific F-actin binding protein I 377 
(neurabin-I) 29 as the predominant antigenic targets of the BCR from PCNSLs. The 378 
specificity of the PCNSL BCRs was not only demonstrated by the negative reaction 379 
of the PCNSL-BCRs with the remaining >7000 other proteins represented in the 380 
macroarray used for screening, but also by the absence of any reactivity against 381 
>200 pathogens including various bacterial, fungal, parasitic and viral pathogens. 382 
The recombinant BCRs in the present study were not reactive against galectin-3 383 
(supplementary figure 17).12 Moreover, SAMD14/neurabin-I are specific antigens of 384 
PCNSL-derived BCRs, because none of the BCRs derived from 12 DLBCL, 19 MCL, 385 
31 follicular lymphoma and 15 NLPHL cases reacted with these proteins which are 386 
preferentially expressed in the CNS.   387 
SAMD14 and neurabin-I share a highly homologous SAM domain, neurabin-I has a 388 
further SAM-like neurabin domain, and both SAMD14 and neurabin-I are primarily 389 
expressed in the CNS (www.proteinatlas.org and www.genevisible.com). The 390 
SAMD14 gene, located on chromosome 17q21.33, consists of 14 exons and a 391 
coding sequence of 417 amino acids. Little is known about the function of SAMD14. 392 
The gene coding for neurabin-I, also called protein phosphatase 1 regulatory subunit 393 
9A (PPP1R9A) is located on chromosome 7q21.3 and has 29 exons with 5 different 394 
splicing forms with coding sequences from amino acids 1095 to 1374. Among other 395 
functions, neurabin-I is a regulator of protein phosphatase 1 (PP1) and binds 396 
specifically to F-actin from neural tissues. Overexpression was observed in the 397 
dorsolateral prefrontal cortex of bipolar disorder and is believed to interact with 398 
NMDA receptor signaling pathways that regulate the actin cytoskeleton and spines of 399 
dendritic cells.30 Moreover, neurabin-I was found to be specifically overexpressed in 400 
hepatosplenic T-cell lymphoma.31  401 
SAMD14 and neurabin-I were N-hyperglycosylated in all patients with PCNSL-402 
derived BCRs with reactivity for these antigens, but not in any other patient or control. 403 
Posttranslationally modified antigens are a well-known phenomenon in autoimmunity 404 
17;32-35. The associated autoreactive BCRs and antibodies are either specifically 405 
reactive against the posttranslationally modified autoantigenic isoforms,17;33 while for 406 
other antigens the BCRs or paraproteins did not differentiate between the 407 
posttranslationally modified and the wild-type isoform.10;34;36;37 The latter is also the 408 
case for the PCNSL-derived BCRs in this study, which reacted with both the normally 409 
glycosylated and the hyper N-glycosylated SAMD14 and neurabin-I isoforms. 410 
Peptides of hyper-N-glycosylated SAMD14/neurabin-I are probably specifically 411 
recognized by CD4+ T cells, which stimulate non-isoform-specific SAMD14/neurabin-412 
I reactive B cells similar to hyperphosphorylated SLP2 in plasma cell disorders.38 413 
SAMD14/neurabin-I autoantibodies showed no light chain restriction, but were 414 
observed in high titers in serum and CSF, indicating two things: First, it suggested a 415 
partly intrathecal production, and second, they probably do not originate directly from 416 
the lymphoma cells, but from related polyclonal B cells with the same specificity that 417 
have undergone plasmablastic differentiation, in contrast to the IgM+ and IgD+ 418 
PCNSL cells, which characteristically stop differentiation before class switch.39  419 
For SAMD14 the residue of ASN 339 and for neurabin-I the residue of ASN 1277 420 
were identified as the sites of N-hyperglycosylation. Interestingly, these two N-421 
glycosylation sites are made of atypical N-L-E-Q patterns, which might further trigger 422 
autoimmunity. Functional effects of the N-hyperglycosylation of both proteins are not 423 
clear and remain to be analyzed in future studies. 424 
In the era of stereotactic biopsies expression cloning of recombinant BCRs from 425 
PCNSL tissue represents a particular challenge because of the rare availability of 426 
sufficient fresh tissue. Despite the cooperation of the major PCNSL centers in the 427 
German-speaking countries, many PCNSL specimens included in this study were 428 
rather old (the oldest more than 25 years) and it was impossible to obtain sera or 429 
CSF from all patients of whom cryospecimens were analyzed. Therefore, for the 430 
analysis of serum and CSF samples, we had to turn to a second cohort of patients. 431 
The detection of polyclonal antibodies against SAMD14/neurabin-I, which were found 432 
in the sera and CSF of nearly one-third of patients in a second (independent) PCNSL 433 
validation cohort, supports the hypothesis that the malignant transformation evolves 434 
from a polyclonal B-cell response against the N-hyperglycosylated and primarily in 435 
the CNS expressed SAMD14 and neurabin-I autoantigens as a non-random early 436 
step in PCNSL, followed by transformation of a subset of SAMD14/neurabin-I-437 
reactive B-cells into a malignant clone.  438 
To investigate if the reactivity of the lymphoma BCRs against SAMD14 and neurabin-439 
I continues to play a sustaining role for established aggressive lymphoma, three 440 
different ABC type DLBCL cell lines, which are biologically closely related to PCNSL 441 
and represent different mutational backgrounds,23-26 were transfected to express a 442 
SAMD14/neurabin-I-reactive BCR, as no established EBV-negative PCNSL cell line 443 
exists so far. Addition of the antigen SAMD14/neurabin-I to this transfected cell lines 444 
resulted in a strong BCR pathway activation accompanied by elevation of 445 
cytoplasmatic calcium levels, a stronger expression of c-Myc and a significantly 446 
increased proliferation. 447 
The results of this study support the hypothesis that activation of the lymphoma 448 
BCRs by their cognate CNS antigen produces a strong growth advantage even for 449 
the transformed aggressive lymphoma cells. This is also supported and might explain 450 
the persistence of functional BCRs in PCNSL despite ongoing somatic 451 
hypermutation. The proliferative effects of the chronic BCR activation by SAMD14 452 
and neurabin-I together with the fact that both SAMD14 and neurabin-I are 453 
predominantly expressed in the CNS 29 serve also as an explanation for the CNS 454 
tropism of the respective lymphomas (Supplementary Figure 20: scheme of 455 
suspected role of SAMD14/neurabin-I).  456 
Finally, the specific reactivity of lymphoma BCRs from the majority of patients with 457 
PCNSL against SAMD14 / neurabin-I might provide the basis for a specific 458 
therapeutic approach that uses BCR antigens for reverse targeting (BARs). Since 459 
SAMD14/neurabin-I are cytoplasmic proteins, treatment strategies using 460 
SAMD14/neurabin-I as a targeting moiety for directing a toxic payload to tumor cells 461 
should not bind to cells expressing membrane receptors other than a BCR with 462 
specificity for SAMD14/neurabin-I. Because it is the major physiologic task of the 463 
BCR to bind and internalize its specific antigen, SAMD14/neurabin-I BARs were 464 
readily internalized (data not shown) and - when conjugated to a toxin - killed the 465 
lymphoma cells after release of the toxin (ETA) with 100% of the cells being dead 466 
after 72 hours as demonstrated by cytotoxicity and apoptosis assays (Figure 4b) and 467 
dye exclusion. In contrast to approaches that target the idiotypic region of the BCR 468 
and must be designed for each individual patient, due to the predominance of BCRs 469 
with specificity for SAMD14/neurabin-I in PCNSL, SAMD14/neurabin-I can be used 470 
as bait to target a majority of patients with PCNSL.40;41 Beside drug-conjugates, the 471 
epitope regions of SAMD14 and neurabin-I could as well be conjugated to or used as 472 
the targeting moiety of CAR-T cells, thus binding to and activating T-cells against the 473 
BCR-expressing cells. Because approaches using the BCR antigen for targeting the 474 
malignant B cells have a higher specificity, they can be expected to be less toxic than 475 
the currently available bispecific T-cell engaging antibodies or CAR-T-cells with 476 
specificity for CD19.41 477 
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 626 
Figure Legends: 627 
Figure 1: SAMD14 and neurabin-I as target antigen of recombinant PCNSL-628 
derived B-cell receptors. a: ELISA of SAMD14 reactivity of PCNSL-derived 629 
recombinant B-cell receptors. The columns represent adsorbance at OD 490nm. 630 
b: Western blots of PCNSL tissue lysates using SAMD14-specific recombinant 631 
BCR. Lane 1: PCNSL tissue from patient #3 with a BCR not reacting with SAMD14; 632 
lane 2: PCNSL tissue from patient #6 with SAMD14 reactive BCR. Two proteins, one 633 
at 150kDa (above) and at 45kDa (bottom) of PCNSL are targeted by the recombinant 634 
BCR, with both antigens from patient #6 having a higher molecular weight compared 635 
to the antigens from patient #3. c: Identification of neurabin-I as the second 636 
antigen. Western blot of PNCSL tissue from patient #3: lane 1: the SAMD14 specific 637 
recombinant BCR targets proteins at 130kDa and 40kDa; lane 2: stripped Western 638 
blot for reprobing with a commercial antibody directed against the N-terminus of 639 
neurabin-I, identified the 130 kDa band as neurabin-I. d: 2nd isoform of SAMD14 / 640 
neurabin-I in patients with SAMD14/neurabin-I-reactive lymphoma BCR. 641 
Western blots of PNCSL tissues from patients with SAMD-14/neurabin-I specific 642 
lymphoma cell BCRs (lanes II, III, IV and V) showed a higher molecular weight than 643 
from patients with BCR specificities other than SAMD-14/neurabin-I (lanes I, VI and 644 
VII), while bands for progranulin were not different. E: ELISA for neurabin-I 645 
reactivity of individual PCNSL-derived recombinant BCRs. The columns 646 
represent adsorbance at OD 490nm consistent with reactivity of the respective 647 
recombinant BCRs against neurabin-I.  648 
 649 
Figure 2: N-Hyperglycosyation of SAMD14 and neurabin-I in PCNSL. a: N-650 
hyperglycosylation of SAMD14 and neurabin-I in patients with 651 
SAMD14/neurabin-I-reactive lymphoma BCRs. Deglycosylation of SAMD14 and 652 
neurabin-1 from PCNSL tissue with a panel of endo- or exoglycosidases  (PNGase-F, 653 
O-glycosidase, neuraminidase, ß-n-acetylglycosidase and galactosidase). Top: Lane 654 
1: untreated PCNSL tissue from patient #3 (without SAMD14 reactive lymphoma 655 
BCR); lane 2: PNGase-F treated PCNSL tissue from #3. Lane 3: untreated PCNSL 656 
tissue from a patient #6 (with SAMD14 reactive lymphoma BCR); lane 4: PNGase-F 657 
treated PCNSL tissue from #6. Lane 5: O-glycosidase treated PCNSL tissue from #3; 658 
lane 6: O-glycosidase treated PCNSL tissue from #6. Lane 7: α-2(3,6,8,9)-659 
neuraminidase treated PCNSL tissue from #3; lane 8: α-2(3,6,8,9)-neuraminidase 660 
treated PCNSL tissue from #6. Bottom: Lane 1: untreated PCNSL tissue from patient 661 
#3; lane 2: PNGase-F treated PCNSL tissue from #3. Lane 3: untreated PCNSL 662 
tissue from #6; lane 4: PNGase-F treated PCNSL tissue from patient #6. Lane 5: β-663 
N-acetylglucosaminidase treated PCNSL tissue from #3; lane 6: β-N-664 
acetylglucosaminidase treated PCNSL tissue from #6. Lane 7: β-1→4-galactosidase 665 
treated PCNSL tissue from #3; lane 8: β-1→4-galactosidase treated PCNSL tissue 666 
from #6. The treatment with PNGase-F and β-N-acetylglucosaminidase resulted in 667 
the disappearance of the differences in molecular weights of both antigens from 668 
patients #3 and #6. b: Deglycosylation of SAMD14 and neurabin-1 from PCNSL 669 
tissue only with ß-n-acetylglycosidase. The treatment with β-N-670 
acetylglucosaminidase resulted in the disappearance of the differences in molecular 671 
weights of both SAMD14 and neurabin-I from patients #3 and #6 c: Identification of 672 
the hyperglycosylated Asn residues. Western blots of several constructs of 673 
SAMD14 and neurabin-I with different mutants of N-glycosylation sites expressed in 674 
LCLs derived from patients with and without hyperglycosylated SAMD14 and 675 
neurabin-I. Anti-FLAG antibodies were used as primary antibodies. These Western 676 
blots showed the disappearance of the gain in molecular weight for the point-677 
mutated, full-length proteins N339Q SAMD14 and N1277Q neurabin-I expressed in 678 
LCLs of PCNSL patients with SAMD14/neurabin-I antibodies. d: Identification of the 679 
hyperglycosylated Asn residues. Western blots of several constructs of SAMD14 680 
and neurabin-I with different mutants of N-glycosylation sites expressed in LCLs 681 
derived from patients with and without hyperglycosylated SAMD14 and neurabin-I. 682 
Instead Anti-FLAG primary antibody recombinant SAMD14/neurabin-I-specific Fab 683 
was used as primary antibody. These Western blots show double bands as they 684 
unspecifically stain for both wild-type SAMD14 (hyperglycosylated) and non-685 
hyperglycosylated N339Q SAMD14 and both for wild-type neurabin-I 686 
(hyperglycosylated) and N1277Q neurabin-I. 687 
 688 
Figure 3: BCR pathway activation and proliferation induced by BCR-specific 689 
antigens. a: Activation of the BCR signaling pathway. The Western blot analysis 690 
of the BCR signaling pathway shows a strong activation by addition of SAMD14 in 691 
transfected TMD8 and U2932 cells expressing a SAMD14/neurabin-I-reactive BCR or 692 
by addition of anti-IgM. The addition of the cognate antigens or anti-IgM antibody 693 
results in the upregulation of pTyr525/526 SYK, pTyr96 BLNK, pTyr759 PLCγ2 and 694 
pTyr223 BTK and led to an overexpression of c-Myc. b:. Proliferation induction of 695 
aggressive lymphoma cell lines by BCR-specific antigens. The columns 696 
(formazan at an OD of 450 nm) represent the proliferation of cells measured by 697 
reduction of tetrazolium salt to colored formazan by viable cells (EZ4U assay). 698 
Addition of epitope containing region of neurabin-I resulted in a significant increase in 699 
proliferation of TMD8 and U2932 cells expressing SAMD14/neurabin-I-reactive 700 
BCRs.  701 
 702 
Figure 4: Specific killing of aggressive lymphoma cells using BCR-703 
antigen/toxin constructs. a: LDH-release assay. Percent specific lysis of non-704 
transfected OCI-Ly3 cells or OCI-LY3 cells transfected to express either MAZ-specific 705 
or SAM-specific BCRs after incubation with 5 μg/mL neurabin-I/ETA or MAZ/ETA, 706 
respectively,for 24h. b: Trypan blue exclusion assay. Cell viability of transfected 707 
OCI-LY3 cells expressing SAMD14/neurabin-I-specific BCRs or non-transfected OCI-708 
Ly3 cells after incubation with 2 µg/mL neurabin-I/ETA or MAZ/ETA was determined 709 
by trypan blue staining after 24h and 48h showing the time-course effect. c: Dose 710 
dependency of cytotoxicity determined by LDH-release assay. Percent specific 711 
lysis of transfected TMD8 cells either Doxycyclin-induced or non-induced after 712 
incubation with different concentrations 1.25 – 10 µg/mL of neurabin-I/ETA’ or 713 
LRPAP1/ETA’ immunotoxins for 24h showing a dose-dependent effect. d: Annexin-714 
V assay. Characterization of transfected TMD8 and U2932 cells with either 715 
Doxycyclin-induced expression of SAMD14/neurabin-I reactive BCR or non-induced, 716 
non-expressing recombinant BCRs by annexin-V and PI staining after 24h cultivation 717 
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